港股異動 | 遠大醫藥(0512.HK)反彈逾5% 針對“新冠”的DNA疫苗啟動 I 期臨牀試驗
格隆匯11月4日丨近期弱勢的遠大醫藥(0512.HK)反彈5.17%,盤中一度升超8%,暫成交1705萬港元,總市值231億港元。遠大醫藥3日公告,美國FDA批准COVID-19疫苗項目CORVax12進行I期臨牀試驗。該疫苗是目前唯一使用免疫刺激劑來促進對SARS-CoV-2病毒免疫反應的DNA疫苗,旨在作為預防性疫苗預防COVID-19。此外,日前澳大利亞生物技術公司Telix與遠大醫藥結成中國市場合作夥伴,Telix將以每股1.69澳元的價格向遠大醫藥定向增發,遠大醫藥將持有Telix約7.62%的股份,收購價2500萬美元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.